AtheroNova begins Phase 1 trial of atherosclerosis drug candidate

Designed to assess ascending doses of AHRO-001 in healthy adult volunteers, the randomized, double-blind study is being conducted in Russia with AtheroNova’s licensing partner, OOO CardioNova.

The safety, tolerability and pharmacokinetic profile of the potential atherosclerosis drug candidate will be evaluated in the placebo controlled study.

AtheroNova chairman and chief executive officer Thomas Gardner said, "Based on AHRO-001’s preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile."